Fabry disease is associated with significant cardiovascular complications, which are major contributors to morbidity and mortality. Key cardiac manifestations include left ventricular hypertrophy, myocardial fibrosis, and heart failure, often leading to arrhythmias and premature death if not properly managed. Early diagnosis and treatment, such as enzyme replacement therapy, are crucial to slow disease progression and prevent severe cardiac complications.
Recent studies highlight the importance of advanced imaging techniques like cardiac MRI for diagnosing and staging Fabry disease-related cardiac issues. These techniques help identify risk factors such as diffuse fibrosis and left ventricular dysfunction, which are linked to adverse outcomes[3]. The high mortality rate associated with Fabry disease underscores the need for comprehensive management strategies to mitigate cardiovascular events in affected patients (Yang and Zhao, 2025).
Clinical Trials
This is a list of upcoming or ongoing clinical trials that are actively recruiting and have been listed or updated in the last two weeks:
